Related Experiment Video
Updated: Jun 9, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Local Treatment (Primary Tumor and Metastases) in Metastatic Prostate Cancer
Nicolas Benziane-Ouaritini1, Alberto Bossi2, Paul Sargos3
1Department of Radiotherapy, Centre Azuréen de Cancérologie, Mougins, France..
Abstract:
For patients with low-volume de novo metastatic hormone-sensitive prostate cancer, addition of an androgen receptor pathway inhibitor and prostate radiotherapy to the standard (SOC) improves survival in comparison to the next most effective strategy (SOC + ARPI). For the subgroup with prior definitive treatment of the primary tumor, long-term outcomes and genomic predictors of response to metastasis-directed therapy suggest that this might be a reasonable option in selected patients.

